Quality of life and costs of spasticity treatment in German stroke patients

Reinhard Rychlik, Fabian Kreimendahl (), Nicole Schnur, Judith Lambert-Baumann and Dirk Dressler
Additional contact information
Reinhard Rychlik: Institute of Empirical Health Economics
Fabian Kreimendahl: Institute of Empirical Health Economics
Nicole Schnur: Merz Pharmaceuticals
Judith Lambert-Baumann: Merz Pharmaceuticals
Dirk Dressler: Hannover Medical School

Health Economics Review, 2016, vol. 6, issue 1, 1-9

Abstract: Abstract Objective To gather data about the medical and non-medical health service in patients suffering from post-stroke spasticity of the upper limb and evaluate treatment effectiveness and tolerability as well as costs over the treatment period of one year. Methods Prospective, non-interventional, multicenter, parallel-group study comparing effectivenessand costs of incobotulinumtoxinA (INCO) treatment (n = 118) to conventional (CON) antispastic therapy (n = 110) for upper limb spasticity after stroke in 47 clinical practices across Germany over a 1-year treatment period. IncobotulinumtoxinA was applied according to the individual treatment algorithms of each participating site and additional antispastic treatments were allowed. Primary efficacy objective was the reduction of the muscle tone measured by Ashworth scale. Responder analyses and logistic regressions were performed. Quality of life, measured by SF-12 questionnaire and functional disability were assessed. Besides calculating treatment costs, a cost-utility analysis was performed. Results Responder rates of all muscle groups of the upper extremities were significantly higher in the treatment group (62.9–86.2 % vs. 15.5–26.9 %, p

Keywords: Post-stroke spasticity; IncobotulinumtoxinA; Cost-utility; Ashworth score (search for similar items in EconPapers)
JEL-codes: I10 I12 (search for similar items in EconPapers)
Date: 2016
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1186/s13561-016-0107-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:hecrev:v:6:y:2016:i:1:d:10.1186_s13561-016-0107-5

Ordering information: This journal article can be ordered from
http://www.springer.com/journal/13561

DOI: 10.1186/s13561-016-0107-5

Access Statistics for this article

Health Economics Review is currently edited by J. Matthias Graf von der Schulenburg

More articles in Health Economics Review from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().